HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries
Open Access
- 27 March 2017
- journal article
- research article
- Published by Elsevier BV in Health Policy
- Vol. 123 (2), 140-151
- https://doi.org/10.1016/j.healthpol.2017.03.009
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studiesOrphanet Journal of Rare Diseases, 2012
- Access to orphan drugs despite poor quality of clinical evidenceBritish Journal of Clinical Pharmacology, 2011
- A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory studyHealth Economics, Policy and Law, 2010
- A comparative study of European rare disease and orphan drug marketsHealth Policy, 2010
- Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67BMJ, 2010
- Is it time to revisit orphan drug policies?BMJ, 2010
- How much is the life of a cancer patient worth? A pharmaco-economic perspectiveJournal of Clinical Pharmacy & Therapeutics, 2010
- History of HTA: IntroductionInternational Journal of Technology Assessment in Health Care, 2009
- Orphan drug development is not taking offBritish Journal of Clinical Pharmacology, 2009
- Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policyCMAJ : Canadian Medical Association Journal, 2006